{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG002","value":"11"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG002","value":"2"}]}],"title":"Very Good Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Complete Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"27"}],"units":"Participants"}],"description":"The number of patients achieving a complete response (CR) or partial response (PR). Response is defined by the International Myeloma Working Group as:\n\nCR- Negative immunofixation on serum and urine and disappearance of soft tissue plasmacytomas and \\< 5% plasma cells in bone marrow\n\nPR- \\> 50% reduction of serum M-protein and urine M-protein by \\>90% or to \\< 200 mg/24 h In addition, if present at baseline, a \\> 50% reduction in the size of soft tissue plasmacytomas is also required\n\nVGPR - Serum and urine M-protein detectable by immunofixation but n","groups":[{"description":"* Pomalidomide: once daily oral (PO) dosing on days 1-21, every 28 days\n* Bendamustine: once intravenous (IV) dosing on day 1, every 28 days\n* Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days\n\nAfter 6 cycles of treatment, dexamethasone may be decreased to 20mg. After total 12 cycles of treatment, subjects will proceed to the maintenance phase until time of progression.\n\nStudy treatment will be administered starting at Cohort 1 for up to four sequential cohorts, with 3-6 patients in each cohort.","id":"OG000","title":"Cohort 1: 120mg Bendamustine + 3mg Pomalidomide"},{"description":"* Pomalidomide: once daily oral (PO) dosing on days 1-21, every 28 days\n* Bendamustine: once intravenous (IV) dosing on day 1, every 28 days\n* Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days\n\nAfter 6 cycles of treatment, dexamethasone may be decreased to 20mg. After total 12 cycles of treatment, subjects will proceed to the maintenance phase until time of progression.\n\nStudy treatment will be administered starting at Cohort 1 for up to four sequential cohorts, with 3-6 patients in each cohort.","id":"OG001","title":"Cohort 2: 120mg Bendamustine + 4mg Pomalidomide"},{"description":"* Pomalidomide: once daily oral (PO) dosing on days 1-21, every 28 days\n* Bendamustine: once intravenous (IV) dosing on day 1, every 28 days\n* Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22 every 28 days\n\nAfter 6 cycles of treatment, dexamethasone may be decreased to 20mg. After total 12 cycles of treatment, subjects will proceed to the maintenance phase until time of progression.\n\nStudy treatment will be administered at the Maximum Tolerated Dose.","id":"OG002","title":"Expansion: 120mg Bendamustine + 3mg Pomalidomide"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The overall number of participants analyzed reflects those who received at least 2 cycles of treatment. These participants were assessed for response at that time. The data reported indicates how many patients out of each cohort experienced at least a partial response or complete response.","reportingStatus":"POSTED","timeFrame":"2 cycles (approximately 2 months)","title":"Initial Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}